Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Concurrent Sunitinib, Temozolomide and Radiation Therapy Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients With an Unmethylated MGMT Gene Promoter

NCT02928575 is registered in ClinicalTrials.gov with Bassam Abdulkarim as lead sponsor.

NCT NCT02928575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02928575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Concurrent Sunitinib, Temozolomide and Radiation Therapy Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients With an Unmethylated MGMT Gene Promoter
Lead sponsor
Bassam Abdulkarim
Phase
Phase 2
Overall status
Unknown status
Start date
August 31, 2012
Completion date
June 30, 2017
Enrollment
45 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme